Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of the study is to determine whether the HPMC capsule of D961H 40 mg is bioequivalent to gelatine capsules of D961H 40 mg after a steady state is reached on Day 5

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Healthy Japanese

• Classified as homo-EM

• Negative for HIV, Hepatitis B, Hepatitis C and syphilis

Exclusion Criteria:

• Significant clinical illness from 2 weeks preceding the pre-entry visit to the randomization

• Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease